Navigation Links
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
Date:4/15/2008

ss or implied discussions regarding potential future regulatory filings or marketing approvals for FTY720 or regarding potential future revenues from FTY720. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with FTY720 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that FTY720 will be submitted to regulatory authorities for approval, or will be approved for sale in any market. Nor can there be any guarantee that FTY720 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding FTY720 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseas
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
2. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
6. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
7. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
8. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
9. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
10. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
11. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... WORTH, Texas, March 22, 2012  The Board of Directors of ... innovator in advanced wound care solutions, announced today that Robert ... of the Company.  In addition, Scott A. Haire has resigned ... Executive Officer of the Company, and Deborah Jenkins Hutchinson has ...
... 22, 2012  Argon Medical Devices, Inc. announced today ... catheter, licensed from Rex Medical, LP, designed to ... treatments. "UltraStream provides clinicians with an ... life for their patients," commented George Leondis, President ...
Cached Medicine Technology:Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 2Wound Management Technologies Names Robert Lutz, Jr. as New CEO; Buys Back North American Distribution Rights for CellerateRX® Powder 3Argon Medical Devices Announces The Launch of a Unique New Chronic Hemodialysis Catheter 2
(Date:7/11/2014)... AngelWeddingDress is now providing worldwide clients ... collections ”. When it comes to buying summer wedding ... with the unlimited stock of beautiful wedding gowns. Recently, ... wonderful summer wedding gowns. , The company’s current ... keep pace with the newest fashion trends. The top ...
(Date:7/11/2014)... OR (PRWEB) July 11, 2014 Recent research ... life, health, the atmosphere, and how water affects human bodies. ... Water, Gerald Pollack, during an interview on the Sharon Kleyne ... , Gerald Pollack, PhD, is a Professor ... is The Fourth Phase of Water (Ebner & Sons, 2013). ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 American Farmer ... RFD-TV, next Tuesday, July 15, 2014, at 8:30 am ... line of proprietary products, which are designed and formulated ... Audiences will learn how these products help the crop ... in which it is grown. , The show also ...
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic variations called ... patients respond to treatment with pemetrexed (Alimta), the most ... full story. Click here to read the new ... Ljubljana and the Ljubljana Institute of Oncology tested ... polymorphisms. They found that patients with genetic variations in ...
(Date:7/11/2014)... Alliance Labs announced that they will be ... Begley Jr, airing later this year 2014, via Discovery ... episode, Innovations will explore DocuSol® Kids, a mini-enema containing ... glycol base designed to give adolescents general constipation relief. ... a hyperosmotic laxative by drawing water into the bowel ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 2Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 3Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2
... at settling a long-standing question among doctors has found that ... patients avoid recurrent strokes. Many doctors suspected that Warfarin was ... both views, showing the two drugs are equals in both ... and blood clots are involved in the final stages of ...
... immunodeficiency virus is a retrovirus that binds to receptors found ... a cell, the virus is internalized, copied into DNA, then ... of the host DNA. In many cases, the inserted viral ... more years. AIDS or Acquired Immune Deficiency Syndrome is a ...
... uterus, the more likely she is to have a miscarriage, ... Journal of Medicine details the most precise information the timing ... its success or failure. ,Fertilised eggs can attach themselves ... 12 days after ovulation, the researchers from the National Institute ...
... too soon is more likely to produce stressed-out toddlers ... targets for three to five-year olds could lead to ... than achieve accelerated learning, says the report. ... early start to their schooling and may revert to ...
... risks,say the researchers.Traditional student digs with mouldy and damp ... ,A study of over 20,000 Finnish students found that ... of asthma, but left residents with a greater chance ... damp houses were found to need more antibiotics than ...
... a virus is possibly resposible for infertility.The virus is ... of testicular tissue taken from men whose semen was ... more frequently than in those with normal semen. ... Heidelberg, which conducted the research, said the virus should ...
Cached Medicine News:Health News:More about HIV 2Health News:More about HIV 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: